secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001104659-25-071769
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals loses jury verdict in royalty dispute with CG Oncology; no damages awarded
--------------------------------------------------------------------------------

- Jury returned verdict on July 29, 2025 awarding no damages to ANI on its unjust enrichment counterclaim against CG Oncology.
- Court previously granted CG Oncology's partial summary judgment on Brulotte defense, finding royalty provision unenforceable.
- ANI intends to challenge the verdict through post-trial motions and/or an appeal.
- Case stems from a 2010 Agreement for a 5% royalty on worldwide net sales of cretostimogene.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000110465925071769/0001104659-25-071769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000110465925071769/tm2522000d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-071769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer